首页 Acceleron制药(usXLRN)-基本信息

Acceleron制药(usXLRN)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:124.34

最高价:124.38

成交量:236599.0

昨收价:124.03

最低价:121.36

最新价:122.05

行情图标
概要信息

中文名称:Acceleron制药


英文名称:Acceleron Pharma


简介:Acceleron Pharma Inc.在特拉华州注册成立于2003年6月13日,凤凰制药公司,公司随后更名为加速子制药公司,并在2004年2月开始运营的公司是剑桥,马萨诸塞州的生物制药公司,专注于这是基于人体用来调节其细胞和组织的生长和修复的机制,新的治疗候选人的发现,开发和商业化


电话:1-617-6499200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Acceleron制药公司是一个临床阶段的生物制药公司,专注于发现、开发和商业化应用蛋白质疗法治疗癌症和罕见疾病的研究。公司与同行Celgene公司达成合作协议。公司的候选产品主要包括luspatercept和sotatercept,用于治疗ß地中海贫血症和骨髓增生异常综合征及其并发症等,目前处于III期临床试验阶段。同时,sotatercept也用于增加骨矿物质密度,治疗慢性肾脏疾病和末期肾脏疾病等。此外,Acceleron Pharma的候选产品dalantercept,可用于治疗肾细胞癌和肝癌。候选产品ACE-083用于促进肌肉生长和功能恢复以及治疗肌肉萎缩,处于一期临床试验阶段。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-15 Veness (Adam M) General Counsel Sell 538 40.71
2019-07-08 Quisel John D Officer Buy 2346 5.28
2019-07-08 Quisel John D Officer Buy 1562 7.12
2019-07-08 Quisel John D Officer Buy 5000 3.88
2019-06-27 George (Jean M) Director Sell 11812 41.17
2019-06-25 George (Jean M) Director Buy 11812 --
2019-06-25 George (Jean M) Director Buy 7500 30.17
2019-06-25 George (Jean M) Director Buy 10000 27.97
2019-06-25 George (Jean M) Director Sell 25688 39.16
2019-06-25 George (Jean M) Director Sell 11812 --
2019-06-25 George (Jean M) Director Buy 20000 24.11
2019-06-13 Zakrzewski (Joseph S. JR) Director Buy 5000 38.05
2019-06-04 Veness (Adam M) General Counsel Buy 1100 --
2019-04-08 Quisel John D Chairman of the Board Sell 100 45.46
2019-04-08 Quisel John D Chairman of the Board Sell 70 44.24
2019-04-08 Quisel John D Chairman of the Board Sell 3452 44.62
2019-04-08 McLaughlin (Kevin F) Chief Financial Officer Sell 100 45.46
2019-04-08 McLaughlin (Kevin F) Chief Financial Officer Sell 11900 44.61
2019-04-08 Kumar Ravindra Officer Sell 100 45.46
2019-04-08 Kumar Ravindra Officer Sell 70 44.24
2019-04-08 Kumar Ravindra Officer Sell 3452 44.62
2019-04-08 Dable (Habib J.) Chief Executive Officer Sell 7214 44.60
2019-04-08 Dable (Habib J.) Chief Executive Officer Sell 146 44.23
2019-04-08 Dable (Habib J.) Chief Executive Officer Sell 100 45.46
2019-04-01 McLaughlin (Kevin F) Chief Financial Officer Sell 648 48.02

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Eagle Asset Management, Inc. 878577 1.67% 988 0.11% 2019-03-31
Farallon Capital Management, L.L.C. 2375000 4.51% 275000 13.10% 2019-03-31
Fidelity Management & Research Company 2972145 5.64% -8944 -0.30% 2019-07-31
Fidelity SelectCo, LLC 3155058 5.99% -292700 -8.49% 2019-07-31
Vanguard Group Inc 4011248 7.61% 488620 13.87% 2019-03-31
T. Rowe Price Associates, Inc. 4495413 8.53% -520254 -10.37% 2019-03-31
BlackRock Inc 4797511 9.11% 368617 8.32% 2019-03-31
Fidelity Management and Research Company 6356176 12.06% 422871 7.13% 2019-03-31
FMR Inc 7363953 13.98% 435414 6.28% 2019-03-31
BlackRock Fund Advisors 2008665 3.81% 27948 1.41% 2019-07-31
State Street Corporation 1840515 3.49% 376334 25.70% 2019-03-31
Artal Group S A 1650000 3.13% 600000 57.14% 2019-03-31
TimesSquare Capital Management, LLC 920715 1.75% 209900 29.53% 2019-03-31
Fidelity Institutional Asset Management 1007777 1.91% 12543 1.26% 2019-03-31
Great Point Partners LLC 1080113 2.05% 43538 4.20% 2019-03-31
Vanguard Investments Australia Ltd 1247141 2.37% 245 0.02% 2019-07-31
Deerfield Management Co 1255174 2.38% -131367 -9.47% 2019-03-31
HHG PLC 1310533 2.49% 34346 2.69% 2019-03-31
Westfield Capital Management Company, LP 1377123 2.61% 84410 6.53% 2019-03-31
Wellington Management Company LLP 1468279 2.79% 1468279 -- 2019-03-31
SSGA Funds Management Inc 1003800 1.91% 81 0.01% 2019-05-31
BlackRock Asset Management Canada Ltd 1018738 1.93% 17 -- 2019-05-31
Perceptive Advisors LLC 905017 1.72% -623188 -40.78% 2018-12-31
Geode Capital Management, LLC 906926 1.73% 485984 115.45% 2018-12-31
BlackRock Advisors LLC 784937 1.52% 10206 1.32% 2019-02-28
Hillhouse Capital Management, Ltd. 813600 1.57% 113600 16.23% 2018-09-30
Novo A/S 1103937 2.39% -450000 -28.96% 2018-06-30
BlackRock Institutional Trust Company NA 1156031 2.50% 83250 7.76% 2018-06-30
Celgene Corp 6118479 13.88% 745592 13.88% 2017-09-25
State Street Corp 1533710 3.35% 68721 4.69% 2018-06-30
Eventide Asset Management, LLC 529900 1.16% -- -- 2018-06-30
Janus Capital Management LLC 506877 1.11% 506877 -- 2018-06-30
Pictet Asset Management SA 496218 1.08% -19855 -3.85% 2018-06-30
Polar Capital LLP 1072898 2.35% 42898 4.16% 2018-03-31
Brown Investment Advisory Incorporated 504677 1.10% 28806 6.05% 2018-03-31
Goldman Sachs Asset Management LP 495174 1.08% -55881 -10.14% 2018-03-31
Northern Trust Investments N A 437397 0.96% 371 0.08% 2018-03-31
Sectoral Asset Management Inc 712356 1.57% 107399 17.75% 2017-12-31
Citigroup Inc 858293 1.93% 830721 3012.92% 2017-09-30
Oak Ridge Investments, LLC 1226468 3.25% -115363 -8.60% 2016-09-30
Granahan Investment Management Inc.. 817149 2.17% 57530 7.57% 2016-09-30
Morgan Stanley & Co Inc 766138 2.03% 763885 33905.24% 2016-09-30
LAURION CAPITAL MANAGEMENT LP 690000 1.83% 690000 -- 2016-09-30
Qvt Financial LP 636764 1.69% -65646 -9.35% 2016-09-30
Franklin Advisers Inc 494777 1.31% -- -- 2016-09-30
Adage Capital Partners, L.P., and related funds 1772406 3.00% 67457772 -- 1999-11-30
Terrance G. McGuire 2580291 3.00% 98205875 0.10% 1999-11-30
Celgene Corporation 4572887 3.00% 174044079 0.10% 1999-11-30
FMRLLC and affiliates 4837978 3.00% 184133443 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 344995 0.65% -283 -0.08% 2019-06-30
Vanguard Total Stock Market Index Fund 1238083 2.35% 298 0.02% 2019-06-30
Vanguard Small Cap Index 1151160 2.18% 6762 0.59% 2019-06-30
T. Rowe Price Health Sciences Fund 1029587 1.95% -297982 -22.45% 2019-06-30
iShares Russell 2000 ETF 995855 1.89% 15535 1.58% 2019-07-30
BlackRock Health Sciences Opps Port 786900 1.49% -- -- 2019-06-30
Carillon Eagle Small Cap Growth Fund 657640 1.25% -- -- 2019-06-30
Vanguard Small Cap Growth Index Fund 653470 1.24% 2284 0.35% 2019-06-30
T. Rowe Price New Horizons Fund 631628 1.20% -305053 -32.57% 2019-06-30
SPDR 611533 1.16% 11970 2.00% 2019-07-31
Vanguard Extended Market Index Fund 607034 1.15% 2581 0.43% 2019-06-30
T. Rowe Price Small-Cap Stock Fund 570900 1.08% -9400 -1.62% 2019-06-30
Wellington Global Health Care Equity 537835 1.02% 7330 1.38% 2019-03-31
iShares Nasdaq Biotechnology ETF 520090 0.99% 5382 1.05% 2019-07-30
Fidelity Advisor 401500 0.76% -18500 -4.40% 2019-06-30
Artisan Small Cap Fund 399967 0.76% 31337 8.50% 2019-06-30
Janus Henderson Global Life Sciences Fd 394582 0.75% -12157 -2.99% 2019-06-30
iShares US Small Cap ETF (CAD-Hedged) 897142 1.70% -1503 -0.17% 2019-05-30
Franklin Biotechnology Discovery Fund 400477 0.76% -- -- 2019-04-30
Vanguard Small Cap Index Fund 1144383 2.17% 3234 0.28% 2019-04-30
UBS (Lux) EF Biotech (USD) 325485 0.62% 81268 33.28% 2018-12-31
ZIL Blackrock Global Fds Wld Health Sci 292007 0.56% -- -- 2018-11-30
ZIL Blackrock Glbl Wrd Healthscience USD 292007 0.56% -- -- 2018-11-30
T. Rowe Price Instl Small-Cap Stock Fund 288000 0.56% 24600 9.34% 2018-12-31
BGF World Healthscience Fund 292007 0.63% 6100 2.13% 2018-10-31
iShares Russell 2000 Growth ETF 291746 0.63% 1281 0.44% 2018-12-31
Eventide Gilead Fund 401000 0.87% -- -- 2018-06-30
Pictet-Biotech 346579 0.75% -86749 -20.02% 2017-09-30
Artisan Small Cap Investor 248792 0.54% 37250 17.61% 2018-06-30
T. Rowe Price Health Sciences 1331728 2.90% 329593 32.89% 2018-06-30
T. Rowe Price New Horizons 892035 1.95% 180869 25.43% 2018-06-30
Vanguard Total Stock Mkt Idx 963545 2.09% -- -- 2018-07-31
Eagle Small Cap Growth A 657640 1.43% -285204 -30.25% 2018-06-30
BlackRock Health Sciences Opps Inv A 651100 1.42% -- -- 2018-07-31
iShares Nasdaq Biotechnology 518680 1.04% -987 -0.19% 2018-09-12
Janus Global Life Sciences D 506877 1.11% 506877 -- 2018-06-30
T. Rowe Price Small-Cap Stock 495600 1.08% -3000 -0.60% 2018-06-30
Vanguard Extended Market Idx Inv 512642 1.11% 3300 0.65% 2018-07-31
Eventide Gilead N 401000 0.87% -- -- 2018-06-30
Goldman Sachs Small/Mid Cap Growth A 332793 0.73% -- -- 2018-06-30
iShares Russell 2000 Growth 314624 0.63% -303 -0.10% 2018-09-12
Vanguard Small Cap Growth Index Inv 278815 0.61% 3921 1.43% 2018-07-31
T. Rowe Price Instl Small-Cap Stock 236400 0.52% -- -- 2018-06-30
Harbor Small Cap Growth Instl 250810 0.55% -15610 -5.86% 2018-03-31
FIAM Small Company Pool 250100 0.55% -- -- 2018-03-31
Loomis Sayles Small Cap Growth Instl 202278 0.54% -5474 -2.63% 2016-12-31
Oak Ridge Small Cap Growth A 625000 1.66% -130000 -17.22% 2016-11-30
Vanguard Explorer Inv 533600 1.42% -- -- 2016-09-30
Vanguard Explorer Fund 322000 1.00% -- -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 3222920 9.70% -- -- 2015-09-30
iShares Russell 2000 (AU) 344291 1.20% -432 -0.10% 2015-11-19
Fidelity Advisor® Biotechnology Fund 541641 1.60% -- -- 2015-09-30
Fidelity® Select Health Care Portfolio 569316 1.70% -- -- 2015-09-30
Oak Ridge Small Cap Growth Fund 997499 3.00% 120000 13.70% 2015-08-31
Franklin Biotechnology Discovery 325277 1.00% -- -- 2015-07-31

Sujay R. Kango Sujay R. Kango is on the board of Cancer Care, Inc. and Chief Commercial Officer & Senior Vice President at Acceleron Pharma, Inc. In the past he occupied the position of Chief Commercial Officer & Executive VP at Infinity Pharmaceuticals, Inc., Vice President-Oncology Global Commercial at AbbVie, Inc., Vice President-Hepatitis Franchise at Merck & Co., Inc. and VP-Global Marketing & Sales Operations at Onyx Pharmaceuticals, Inc. Sujay R. Kango received an MBA, a graduate degree and an undergraduate degree from McNeese State University.
Francois Nader Founder of Jesra Advisors LLC, Francois Nader is a businessperson who has been at the helm of 7 different companies and presently is Chairman for Talaris Therapeutics, Inc., Non-Executive Chairman of Prevail Therapeutics, Inc., Non-Executive Chairman of Acceleron Pharma, Inc., Chief Executive Officer for Jesra Advisors LLC and President at Jesra Foundation, Inc. Dr. Nader is also on the board of 5 other companies. Francois Nader previously occupied the position of Chief Medical Officer at Care Capital LLC, President, Chief Executive Officer & Director at NPS Pharmaceuticals, Inc., Head-Global Commercial Operations at Rhone-Poulenc Basic Chemical Co., Senior VP-Integrated Healthcare Markets at Hoechst Marion Roussel, Inc. and Senior VP-Integrated Healthcare Markets at Aventis Pharmaceuticals, Inc. Francois Nader received an MBA from the University of Tennessee and a doctorate from St. Joseph University.
Richard F. Pops Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University.
Kevin F. McLaughlin Mr. Kevin F. McLaughlin is an Independent Non-Executive Director at Stealth BioTherapeutics Corp., an Independent Director at Vericel Corp. and a Chief Financial Officer, Treasurer & Senior VP at Acceleron Pharma, Inc. He is on the Board of Directors at Stealth BioTherapeutics Corp. and Vericel Corp. Mr. McLaughlin was previously employed as a Chief Financial Officer & Senior Vice President by Qteros, Inc., a Chief Operating Officer & Director by Aptius Education, Inc., a President, Chief Executive Officer & Director by Praecis Pharmaceuticals, Inc., a Treasurer & Vice President by Computervision Corp., a Treasurer & Vice President by Prime Computer, Inc., and a Chief Financial Officer & Vice President by Advanced TechCom, Inc. He received his undergraduate degree from Northeastern University and an MBA from Babson College.
Richard F. Pops Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University.
Terrence C. Kearney Terrence C. Kearney is on the board of Vertex Pharmaceuticals, Inc., Acceleron Pharma, Inc. and Levo Therapeutics, Inc. In his past career he held the position of Treasurer & Vice President of Abbott Laboratories and Chief Operating Officer of Hospira, Inc. Terrence C. Kearney received an undergraduate degree from the University of Illinois and an MBA from the University of Denver.
Jean M. George Founder of Genzyme Tissue Repair, Jean M. George currently holds the position of General Partner of Lightstone Ventures, Managing Director at LSV Capital Management LLC (a subsidiary of Lightstone Ventures) and General Partner for Advanced Technology Ventures, Managing Director at ATV Associates VII LLC (a subsidiary of Advanced Technology Ventures). Ms. George is also Managing Director at LSV Capital Management LLC and Managing Director at ATV Associates VII LLC and on the board of 9 other companies. In the past Jean M. George occupied the position of Director at NeuroMetrix, Inc., Director at ZELTIQ Aesthetics, Inc., Director at Bioverativ Therapeutics, Inc., Director at Microbia, Inc., Vice President at Genzyme Tissue Repair, Director at NuGenesis Technologies Corp., Director at BancBoston Capital, Inc. and Vice President-Sales & Marketing for Genzyme Corp. She received an undergraduate degree from the University of Maine and an MBA from Simmons School of Management.
Matthew L. Sherman Dr. Matthew L. Sherman, MD, is an Independent Director at Pulmatrix, Inc. and a Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. He is on the Board of Directors at NewLink Genetics Corp. and Pulmatrix, Inc. Dr. Sherman was previously employed as a Chief Medical Officer & Senior Vice President by Synta Pharmaceuticals Corp., an Assistant Clinical Professor by Harvard Medical School, an Assistant Clinical Professor by Dana-Farber Cancer Institute, Inc., a Therapeutic Area Director-Oncology by Genetics Institute LLC, a Professor by The Brigham & Women's Hospital, Inc., a Member by The Marine Biological Laboratory, and a Therapeutic Area Director-Oncology by Wyeth Pharmaceuticals LLC. He received his undergraduate degree from Massachusetts Institute of Technology and a doctorate degree from Dartmouth Medical School.
Joseph S. Zakrzewski Joseph S. Zakrzewski is a businessperson who has been at the head of 6 different companies. Mr. Zakrzewski holds the position of Executive Chairman of Thrasos Therapeutics, Inc. He is also on the board of 10 other companies. Mr. Zakrzewski previously occupied the position of Non-Executive Chairman at Onxeo SA, Chairman for Promedior, Inc., Vice President-Corporate Business Development at Eli Lilly & Co., Chairman & Chief Executive Officer of Amarin Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer at Xcellerex, Inc., Chief Operating Officer for Reliant Pharmaceuticals LLC and Venture Partner at OrbiMed Advisors Private Equity. Mr. Zakrzewski received an MBA from Indiana University and a graduate degree and an undergraduate degree from Drexel University.
Todd James Presently, Todd James occupies the position of VP-Investor Relations & Corporate Communications at Acceleron Pharma, Inc. In the past Mr. James was Vice President at Trout Capital LLC. Mr. James received an undergraduate degree from Moravian College.
George S. Golumbeski Dr. George S. Golumbeski is an Independent Director at Enanta Pharmaceuticals, Inc., an Independent Director at Acceleron Pharma, Inc. and a Chairman at BioSight Ltd. He is on the Board of Directors at MorphoSys AG, Enanta Pharmaceuticals, Inc., Acceleron Pharma, Inc., National Audubon Society, Inc., Tizona Therapeutics, Inc., BioNJ, Inc. and Keck Graduate Institute of Applied Life Sciences. Dr. Golumbeski was previously employed as an Executive Vice President-Business Development by Celgene Corp., a Chief Executive Officer by Nabriva Therapeutics AG, a Vice President-Business Development by Elan Pharmaceuticals, Inc., a VP-Business Development, Licensing & Strategy by Novartis Oncology, Inc., and a Vice President-Corporate Development by SCHWARZ PHARMA, Inc. He received his undergraduate degree from the University of Virginia and a doctorate degree from the University of Wisconsin.
Thomas A. McCourt Thomas A. McCourt founded Astra Merck, Inc. Presently, Mr. McCourt is President at Ironwood Pharmaceuticals, Inc. He is also on the board of Acceleron Pharma, Inc. Mr. McCourt previously was Brand Manager-Prilosec at Astra Merck, Inc. and Vice President-Strategic Marketing & Operations at Novartis Corp. Mr. McCourt received an undergraduate degree from the University of Wisconsin.
James V. Desiderio Presently, James V. Desiderio occupies the position of Vice President-Regulatory Affairs at Acceleron Pharma, Inc. He previously held the position of Principal at Gilead Sciences, Inc., Principal at Bristol-Myers Squibb Co. and Executive Director & Head-Program Management at Idenix Pharmaceuticals LLC. Dr. Desiderio received an undergraduate degree from Long Island University and a graduate degree and an undergraduate degree from College of Veterinary Medicine.
John D. Quisel Presently, John D. Quisel is Chief Business Officer & Executive Vice President at Acceleron Pharma, Inc. In the past he was Principal at Ropes & Gray LLP and Principal at Foley Hoag LLP. He received a graduate degree from Stanford University, a doctorate from Massachusetts Institute of Technology, an undergraduate degree from Harvard University and a graduate degree from Harvard Law School.
John D. Quisel Presently, John D. Quisel is Chief Business Officer & Executive Vice President at Acceleron Pharma, Inc. In the past he was Principal at Ropes & Gray LLP and Principal at Foley Hoag LLP. He received a graduate degree from Stanford University, a doctorate from Massachusetts Institute of Technology, an undergraduate degree from Harvard University and a graduate degree from Harvard Law School.
Ravindra Kumar Ravindra Kumar is Chief Scientific Officer & Senior Vice President at Acceleron Pharma, Inc. In his past career Dr. Kumar held the position of Senior Scientist at Wyeth Pharmaceuticals LLC and Principal Scientist at Genetics Institute LLC. Dr. Kumar received a doctorate from the University of New Brunswick, a graduate degree from Chaudhary Charan Singh University and an undergraduate degree from Mahatma Jyotiba Phule Rohilkhand University.
Christopher Rovaldi Christopher Rovaldi is SVP-Program Management & Operations at Acceleron Pharma, Inc. In the past he held the position of Director-Project Management at Idenix Pharmaceuticals LLC, Senior Research Associate at Periodontix, Inc. and Director-Project Management at Cubist Pharmaceuticals, Inc. Mr. Rovaldi received a graduate degree and an undergraduate degree from the University of New Hampshire.
Sujay R. Kango Sujay R. Kango is on the board of Cancer Care, Inc. and Chief Commercial Officer & Senior Vice President at Acceleron Pharma, Inc. In the past he occupied the position of Chief Commercial Officer & Executive VP at Infinity Pharmaceuticals, Inc., Vice President-Oncology Global Commercial at AbbVie, Inc., Vice President-Hepatitis Franchise at Merck & Co., Inc. and VP-Global Marketing & Sales Operations at Onyx Pharmaceuticals, Inc. Sujay R. Kango received an MBA, a graduate degree and an undergraduate degree from McNeese State University.
Karen L. Smith Presently, Karen L. Smith holds the position of President & Chief Executive Officer at Medeor Therapeutics, Inc. Dr. Smith is also on the board of Antares Pharma, Inc., Sangamo Therapeutics, Inc., Acceleron Pharma, Inc. and Sucampo Pharmaceuticals, Inc. In her past career Dr. Smith held the position of Chief Medical Officer & EVP-Research & Development at Jazz Pharmaceuticals Plc and Director & Vice President at Celator Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc), Head-US Clinical Operations at Bristol-Myers Squibb Co., Chief Executive Officer at Boron Molecular Ltd., SVP-Global Medical Affairs & Head-Dermatology at Allergan, Inc. and Head-External Medical Relations at AstraZeneca LP. Karen L. Smith received a doctorate from the University of Warwick, a doctorate from The University of Western Australia, an MBA from the University of New England (Australia), a graduate degree from the University of Salford and an undergraduate degree from Curtin University of Technology.
Habib J. Dable Presently, Habib J. Dable is President, Chief Executive Officer & Director at Acceleron Pharma, Inc. He is also on the board of Millendo Therapeutics US, Inc. and Millendo Therapeutics, Inc. In the past Mr. Dable was President-US Pharmaceuticals at Bayer AG and EVP & Global Head- Specialty Medicine at Bayer HealthCare Pharmaceuticals, Inc. (a subsidiary of Bayer AG). He received an MBA and an undergraduate degree from the University of New Brunswick.
Karen L. Smith Presently, Karen L. Smith holds the position of President & Chief Executive Officer at Medeor Therapeutics, Inc. Dr. Smith is also on the board of Antares Pharma, Inc., Sangamo Therapeutics, Inc., Acceleron Pharma, Inc. and Sucampo Pharmaceuticals, Inc. In her past career Dr. Smith held the position of Chief Medical Officer & EVP-Research & Development at Jazz Pharmaceuticals Plc and Director & Vice President at Celator Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc), Head-US Clinical Operations at Bristol-Myers Squibb Co., Chief Executive Officer at Boron Molecular Ltd., SVP-Global Medical Affairs & Head-Dermatology at Allergan, Inc. and Head-External Medical Relations at AstraZeneca LP. Karen L. Smith received a doctorate from the University of Warwick, a doctorate from The University of Western Australia, an MBA from the University of New England (Australia), a graduate degree from the University of Salford and an undergraduate degree from Curtin University of Technology.
Adam M. Veness Presently, Adam M. Veness occupies the position of Secretary, Vice President & General Counsel for Acceleron Pharma, Inc.
Kevin McManus Mr. Kevin McManus is a Chief Human Resources Officer at Acceleron Pharma, Inc. He received his undergraduate degree from Cornell University.

量化对比

全部评论 1

  • 【Acceleron肺高压药物试验达到主要目标 股价一度暴涨79%】美国制药商Acceleron Pharma周一表示,其肺动脉高压(PAH)药物sotatercept在中期试验中达到了主要目标,推动其股价盘中一度暴涨79%,收盘上涨66%。肺动脉高压是一种罕见疾病,发作时患者肺部的动脉收缩,迫使心脏更努力工作,往往导致心力衰竭。目前这种疾病无法治愈,但市场上有能够控制病情的治疗药物。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐